In summary, our results indicate that HOXB13 downregulation occurs early at the metastatic processes of PCa, rather than as a consequence of hormone therapy, thus representing a critical therapeutic target in metastatic hormone-sensitive PCa. The gene discussed is HOXB13; the disease is posterior cortical atrophy.